{"product_id":"nvo-bcg-matrix","title":"(NVO) Novo Nordisk A\/S BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Novo Nordisk A\/S BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWegovy 2.4 mg obesity 2021\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWegovy 2.4 mg is Novo Nordisk A\/S’s flagship obesity brand, and 2024 sales reached DKK 58.2bn, showing how central it is to growth. Demand stays strong in a market that is still expanding fast, so supply, access, and promotion remain key to defend share. If growth normalizes, the brand can shift from a Star to a Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOzempic 0.5 to 2 mg T2D 2017\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOzempic is still a Star in Novo Nordisk A\/S's BCG mix: 2024 sales reached about DKK 120.5bn, up 26% year on year, and the brand keeps leading the GLP-1 and type 2 diabetes market. Broad prescriber use and strong real-world awareness support its scale, while Novo Nordisk kept 2025 sales growth guidance at 16% to 24%. That makes Ozempic a core revenue engine as the market keeps expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRybelsus 7 to 14 mg oral GLP-1 2019\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRybelsus, launched in 2019, is the first oral GLP-1 tablet and a clear Star in Novo Nordisk A\/S’s BCG matrix. Its 7 mg to 14 mg dosing broadens semaglutide beyond injections, taps a convenience-led diabetes market, and helps support share gains in a class that keeps growing. It still needs strong commercial push to keep adoption rising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSemaglutide CV risk reduction 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2024, semaglutide’s cardiovascular label broadened the market beyond glucose control and reinforced its Star status for Novo Nordisk A\/S. The SELECT trial showed a 20% cut in major adverse CV events, which strengthened payer interest and supported premium pricing.\u003c\/p\u003e\n\u003cp\u003eThis added clinical value lifted demand for Wegovy and Ozempic, helping the franchise compete better with rival incretin drugs like Eli Lilly’s tirzepatide. Novo Nordisk A\/S reported 2024 revenue of DKK 290.4bn, with obesity care and diabetes growth still driving the mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20% MACE reduction in SELECT\u003c\/li\u003e\n\u003cli\u003eExpanded use beyond glucose control\u003c\/li\u003e\n\u003cli\u003eStronger payer and brand pull\u003c\/li\u003e\n\u003cli\u003eSupports Star territory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiabetes and Obesity Care growth engine 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiabetes and Obesity Care is Novo Nordisk A\/S’s main growth engine, led by Wegovy and Ozempic. In 2025, the unit kept growing fast as obesity, diabetes, and cardiovascular demand stayed strong, but it still needed heavy investment in supply and R\u0026amp;D. Its share position remains one of Novo Nordisk A\/S’s strongest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore growth platform in 2025\u003c\/li\u003e\n\u003cli\u003eDriven by obesity and diabetes demand\u003c\/li\u003e\n\u003cli\u003eNeeds high capex and R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eStrongest market-share position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWegovy and Ozempic Keep Novo Nordisk’s Growth Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWegovy, Ozempic, and Rybelsus stay Stars in Novo Nordisk A\/S’s BCG mix because demand is still rising fast and the GLP-1 market keeps expanding. Wegovy sales hit DKK 58.2bn in 2024, and Ozempic reached about DKK 120.5bn, up 26% year on year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWegovy\u003c\/td\u003e\n\u003ctd\u003eDKK 58.2bn\u003c\/td\u003e\n\u003ctd\u003eObesity growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOzempic\u003c\/td\u003e\n\u003ctd\u003eDKK 120.5bn\u003c\/td\u003e\n\u003ctd\u003eDiabetes scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRybelsus\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eOral GLP-1 reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eNovo Nordisk A\/S BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide investment and divestment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Novo Nordisk BCG Matrix that simplifies portfolio pain points for fast, clear strategic review\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Novo Nordisk A\/S, helping users verify key assumptions quickly and make better decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTresiba 100 and 200 U basal insulin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTresiba 100 and 200 U\/mL is a mature basal insulin with a broad global footprint, so it fits Novo Nordisk A\/S’s Cash Cows bucket. In a low-growth insulin market, demand stays recurring because patients need steady replacement therapy, and the brand still holds meaningful share. That makes cash flow stable, while commercial spend stays lighter than in faster-growing categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovoRapid NovoLog rapid insulin aspart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S’s NovoRapid NovoLog (insulin aspart) is a mature insulin franchise with long-standing physician trust and broad chronic-use demand. In 2025, Novo Nordisk A\/S reported DKK 290.4 billion in revenue, and established insulins like this helped fund growth bets by converting a stable, low-growth base into cash. That steady, repeat prescription stream makes it a clear cash cow in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorditropin somatropin long-running franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNorditropin is a long-running growth hormone franchise with durable demand, and it fits the cash cow role in Novo Nordisk A\/S’s BCG matrix. The brand sits in a low-growth market, but Novo Nordisk’s strong position supports steady margins and recurring cash flow. In 2024, Novo Nordisk reported DKK 290.4 billion in sales, and mature brands like Norditropin help fund growth areas while staying cash generative.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNovoSeven 1996 rare bleeding disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovoSeven, launched in 1996, is a mature hemostasis drug with entrenched use in rare bleeding disorders and inhibitor cases. Its niche specialist base and low direct substitution make demand relatively stable, so it fits the Cash Cow role in Novo Nordisk A\/S BCG Matrix. In FY2024, Novo Nordisk reported DKK 290.4bn in revenue, and NovoSeven remained a steady legacy contributor.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunched in 1996\u003c\/li\u003e\n\u003cli\u003eSpecialist rare-bleeding market\u003c\/li\u003e\n\u003cli\u003eLow substitution risk\u003c\/li\u003e\n\u003cli\u003eStable cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNovoFine NovoTwist pen needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovoFine NovoTwist is a Cash Cow because pen needles sit on a huge installed base of Novo Nordisk injectable users. Demand is recurring and sticky, while volume growth is modest, so the line keeps throwing off steady cash rather than fast growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring use from every injection\u003c\/li\u003e\n\u003cli\u003eLow growth, high repeat demand\u003c\/li\u003e\n\u003cli\u003eScale supports lower unit costs\u003c\/li\u003e\n\u003cli\u003eMargin stays protected by efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk’s Cash Cows: Steady Repeat Revenue from Mature Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows in Novo Nordisk A\/S are mature, repeat-use lines like Tresiba, NovoRapid, Norditropin, NovoSeven, and NovoFine NovoTwist. They sit in low-growth markets but keep producing steady cash because patients and clinics need them again and again.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTresiba\u003c\/td\u003e\n\u003ctd\u003eMature basal insulin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovoRapid\u003c\/td\u003e\n\u003ctd\u003eRecurring chronic use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorditropin\u003c\/td\u003e\n\u003ctd\u003eStable niche demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovoSeven\u003c\/td\u003e\n\u003ctd\u003eRare-disease niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eNovo Nordisk A\/S Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Novo Nordisk A\/S BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the full, ready-to-use report. Once purchased, it’s delivered instantly for download, printing, or presentation. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaxenda 3.0 mg liraglutide 2014\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSaxenda 3.0 mg liraglutide, launched in 2014, is an older obesity brand that has lost momentum as Wegovy 2.4 mg semaglutide and newer incretin drugs took demand. In Novo Nordisk A\/S’s 2025 obesity portfolio, it sits in a slower-growth lane with weaker strategic pull, so it fits a Dog in the BCG matrix. The once-daily injection now looks like a low-priority asset, with growth and capital better directed to newer brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLevemir insulin detemir 2024 exit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLevemir (insulin detemir) is a legacy basal insulin with declining relevance, and Novo Nordisk has already moved away from it in key markets, including the U.S. in 2024. Its growth is weak and its strategic value is low because newer basal insulins and GLP-1 drugs are taking demand. In BCG terms, Levemir fits a Dog: low growth, low share, and little future cash-flow potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFiasp faster aspart 2017\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFiasp, launched in 2017, still has not matched Novo Nordisk A\/S core insulin brands like NovoLog\/NovoRapid, so its share stays small in a mature, crowded insulin market. In 2025, the category was still led by a few giant injectables, while faster-aspart remained a niche option with limited adoption and weaker pricing power. That profile fits dog territory in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXultophy IDegLira 2014\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXultophy IDegLira is a mature combo therapy in a slow, crowded diabetes market, and it has not turned into a major growth engine for Novo Nordisk A\/S. Its visibility is far below semaglutide-led brands like Ozempic and Wegovy, and its share and growth profile remain weak.\u003c\/p\u003e\n\u003cp\u003eIn Novo Nordisk A\/S 2025 reporting, Xultophy stayed a small line item versus the company’s far larger GLP-1 franchise, which drove most of the group’s sales growth. That makes Xultophy a clear Dogs case: low growth, limited strategic pull, and low market momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, weak share, small sales impact\u003c\/li\u003e\n\u003cli\u003eOutshined by semaglutide-based brands\u003c\/li\u003e\n\u003cli\u003eNot a key 2025-2026 growth driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMixtard Protaphane Actrapid legacy insulins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMixtard, Protaphane, and Actrapid are mature human-insulin brands with low strategic value in Novo Nordisk A\/S's BCG matrix. They face pricing pressure from newer analog insulins and GLP-1 drugs; by 2025, Novo Nordisk A\/S's growth was driven by semaglutide-based products, not these legacy lines. So they fit the dog category: low growth, weak share, limited capital priority.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature, price-sensitive brands\u003c\/li\u003e\n\u003cli\u003eLoss share to analog insulin\u003c\/li\u003e\n\u003cli\u003eOutpaced by GLP-1 growth\u003c\/li\u003e\n\u003cli\u003eLow priority for new investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk’s Legacy Brands Fall into the Dog Bucket\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Novo Nordisk A\/S 2025, Saxenda, Levemir, Fiasp, Xultophy, Mixtard, Protaphane, and Actrapid sit in the Dog bucket: mature, low-growth, and losing share to Wegovy, Ozempic, and newer insulins. Levemir was exited from the U.S. in 2024, and Saxenda and Xultophy remain small versus the GLP-1 engine. Capital should stay focused on higher-growth brands.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaxenda\u003c\/td\u003e\n\u003ctd\u003eOlder obesity asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLevemir\u003c\/td\u003e\n\u003ctd\u003eLegacy, declining\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiasp\u003c\/td\u003e\n\u003ctd\u003eNiche share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXultophy\u003c\/td\u003e\n\u003ctd\u003eLow momentum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCagriSema phase 3 obesity pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCagriSema is Novo Nordisk A\/S’s high-upside phase 3 obesity asset, aimed at a market where WHO says over 890 million adults live with obesity. The prize is huge, but sales are still unproven because approval, pricing, and uptake are not locked in. That mix of big demand and high execution risk makes it a classic question mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmycretin phase 1 and 2 obesity asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmycretin is an early but meaningful obesity bet: Novo Nordisk’s phase 1 data showed double-digit weight loss, but the asset is still too new to size share potential. With obesity drugs already driving Novo Nordisk’s 2024 sales to DKK 290.4 billion, the upside is real, yet phase 2 and later readouts must prove durability and safety. That makes Amycretin a classic high-upside Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAwiqli insulin icodec once weekly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAwiqli, the once-weekly insulin icodec, is Novo Nordisk A\/S's first basal insulin with weekly dosing, so it fits a Question Mark: high potential, low proven share. Phase 3 ONWARDS data showed non-inferior HbA1c control versus daily basal insulin, but uptake is still early and payer, doctor, and patient response is not yet clear. If physicians value fewer injections, it could scale fast; if not, share stays untested.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZiltivekimab phase 3 cardiometabolic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZiltivekimab is in phase 3 for inflammation-linked cardiometabolic disease, a market tied to chronic kidney disease and cardiovascular risk, where CKD affects about 1 in 10 adults worldwide. The science is strong, but Novo Nordisk A\/S has not yet proved commercial uptake, pricing power, or label breadth.\u003c\/p\u003e\n\u003cp\u003eThat makes it a question mark in the BCG Matrix: high potential, low certainty. Late-stage success and FDA and EMA progress still have to turn phase 3 data into sales, especially in a space where the addressable patient pool is large but outcomes are not yet validated.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge unmet need, but unproven revenue\u003c\/li\u003e\n\u003cli\u003ePhase 3 execution now drives value\u003c\/li\u003e\n\u003cli\u003eRegulatory approval is still the gate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMim8 phase 3 hemophilia A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMim8 is Novo Nordisk A\/S's phase 3 hemophilia A pipeline asset, aimed at a rare market where hemophilia A affects about 1 in 5,000 male births. The chance is real, but share is unproven, so it fits BCG question mark territory: high need, high uncertainty, and no clear cash engine yet.\u003c\/p\u003e\n\u003cp\u003eIf the phase 3 data and launch land well, Mim8 can move toward star status; if not, it stays a costly bet. In rare-disease drugs, execution matters as much as science, and a small prescriber base can still mean strong value if adoption is fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 3 asset, not yet proven.\u003c\/li\u003e\n\u003cli\u003eRare market, but share is unset.\u003c\/li\u003e\n\u003cli\u003eSuccess depends on trial and launch.\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-reward question mark.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo’s Pipeline: Big Bets, Big Markets, Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion marks in Novo Nordisk A\/S are growth bets with huge markets but no proven sales moat yet. CagriSema, Amycretin, Awiqli, Ziltivekimab, and Mim8 all sit in late or early trials, so value depends on 2025-2026 readouts, approval, and launch uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eWhy it is a question mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCagriSema\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eBig obesity market, unproven sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmycretin\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eEarly data, share unknown\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234735464713,"sku":"nvo-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nvo-bcg-matrix.webp?v=1785726944","url":"https:\/\/dcfanalyst.com\/products\/nvo-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}